Print Print
CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.

Lipid modification - primary and secondary CVD prevention - Management
What drug interactions are associated with bile acid sequestants?

  • Bile acid sequestrants could delay or reduce the absorption of certain drugs in the gastrointestinal tract (e.g. digoxin, verapamil, levothyroxine, tetracycline).
    • To minimize possible interference with absorption, other medications should be taken at least 1 hour before, or 4–6 hours after, taking a bile acid sequestrant.
  • These drugs may also interfere with normal fat absorption and thus may alter the absorption of fat soluble vitamins (vitamins A, D, E, and K) (for further information, see Cautions and contraindications).
  • Bile acid sequestants and warfarin:
    • If concurrent use with colestyramine is necessary, close monitoring of the international normalized ratio (INR) should be considered because:
      • Colestyramine can reduce the anticoagulant effects of warfarin by interfering with warfarin absorption (directly and via the enterohepatic circulation pathway). This interaction is established, but the magnitude and clinical importance is uncertain. Giving colestyramine 3 to 6 hours after warfarin has been shown to minimize the effects of this interaction [Baxter, 2006].
      • Colestyramine may have some direct hypoprothrombinaemic effects by reducing the absorption of vitamin K [Baxter, 2006].
      • Isolated and unexplained reports of paradoxical increases in the effects of warfarin have also been documented [Baxter, 2006].
    • Colesevelam and colestipol: although these drugs have not been shown to have an effect on the bioavailability of warfarin, the manufacturers advise that anticoagulant therapy should be monitored closely. Specific clinical interaction studies with colesevelam and vitamin K have not been performed.

[ABPI Medicines Compendium, 2005a; ABPI Medicines Compendium, 2007a; ABPI Medicines Compendium, 2008a; ABPI Medicines Compendium, 2008d]

© NHS Institute for Innovation and Improvement